Annals of Hematology

, Volume 93, Issue 6, pp 965–975

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)

  • R. Willemze
  • S. Suciu
  • P. Muus
  • C. J. M. Halkes
  • G. Meloni
  • L. Meert
  • M. Karrasch
  • J. Rapion
  • M. Vignetti
  • S. Amadori
  • T. de Witte
  • J. P. Marie
Original Article

Abstract

This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome. In this phase I trial, 25 patients (median age 56 years) received 5 days of clofarabine as 1-h infusion (arm A) or push injection (arm B) at the dose level of 5 × 10 or 5 × 15 mg/m2/day in an algorithmic dose escalation 3 + 3 design. A consolidation course (intermediate dose cytosine arabinoside, idarubicin) was planned for patients in complete remission (CR). Primary endpoint was safety and tolerance as measured by dose limiting toxicity (DLT); secondary endpoints were response rate, other grade III/IV toxicities, and hematological recovery after induction and consolidation. Five DLTs were observed (in arm A: one DLT at 10 mg/m2/day, three at 15 mg/m2/day; in arm B: one DLT at 15 mg/m2/day). Three patients receiving 15 mg/m2/day were withdrawn due to adverse events not classified as DLT. Prolonged hypoplasia was observed in five patients. CR + complete remission with incomplete recovery were achieved in 21 patients (11/12 (92 %) receiving clofarabine 10 mg/m2/day; 10/13 (77 %) receiving clofarabine 15 mg/m2/day). Clofarabine, 5 × 10 mg/m2/day, resulted in one DLT and no early treatment withdrawals. MTD of clofarabine combined with cytosine arabinoside and idarubicin is 5 × 10 mg/m2/day.

Keywords

Acute myeloid leukemia Clofarabine Phase I dose finding study 

References

  1. 1.
    Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G et al (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction an consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27:5397–5403PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P et al (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 Trial. J Clin Oncol 32(3):219–228Google Scholar
  3. 3.
    Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364(11):1027–1036PubMedCrossRefGoogle Scholar
  4. 4.
    de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G et al (2010) Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 95(10):1754–1761PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Burnett A, Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29(5):487–494PubMedCrossRefGoogle Scholar
  6. 6.
    Kantarjian H, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J et al (2003) Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167–1173PubMedCrossRefGoogle Scholar
  7. 7.
    Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G et al (2003) Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379–2386PubMedCrossRefGoogle Scholar
  8. 8.
    Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E et al (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940–947PubMedCrossRefGoogle Scholar
  9. 9.
    Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian H et al (2005) The role of clofarabine in hematologic and solid malignancies—development of a next-generation nucleoside analog. Cancer 103:1985–1995, ReviewPubMedCrossRefGoogle Scholar
  10. 10.
    Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S et al (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28:2389–2395PubMedCrossRefGoogle Scholar
  11. 11.
    Cooper T, Ayres M, Nowak B, Gandhi V (2005) Biochemical modulation of cytarabine-triphosphate by clofarabine. Cancer Chemother Pharmacol 55:361–368PubMedCrossRefGoogle Scholar
  12. 12.
    Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G et al (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108:45–51Google Scholar
  13. 13.
    Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z et al (2008) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112:1638–1645Google Scholar
  14. 14.
    Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F et al (2008) Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113:2090–2096PubMedCrossRefGoogle Scholar
  15. 15.
    Kantarjian H, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T et al (2010) Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549–555PubMedCrossRefGoogle Scholar
  16. 16.
    Agura E, Cooper B, Holmes H, Vance E, Berryman RB, Maisel C et al (2011) Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 16:197–206PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Tse E, Leung AY, Sim J, Lee HK, Liu HS, Yip SF et al (2011) Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol 90:1277–1281PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S et al (2011) Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 155:182–189PubMedCrossRefGoogle Scholar
  19. 19.
    Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G et al (2012) Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118:4471–4477PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 18–30Google Scholar
  21. 21.
    Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925–937PubMedCrossRefGoogle Scholar
  22. 22.
    Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • R. Willemze
    • 1
  • S. Suciu
    • 2
  • P. Muus
    • 3
  • C. J. M. Halkes
    • 1
  • G. Meloni
    • 4
  • L. Meert
    • 2
  • M. Karrasch
    • 2
  • J. Rapion
    • 2
  • M. Vignetti
    • 5
  • S. Amadori
    • 6
  • T. de Witte
    • 3
  • J. P. Marie
    • 7
  1. 1.Department of HematologyLeiden University Medical CenterLeidenThe Netherlands
  2. 2.EORTC HeadquartersBrusselsBelgium
  3. 3.Radboud University Medical CenterNijmegenThe Netherlands
  4. 4.University “Sapienza”RomeItaly
  5. 5.GIMEMA Data CenterRomeItaly
  6. 6.Tor Vergata University HospitalRomeItaly
  7. 7.Hopital Saint AntoineParisFrance

Personalised recommendations